- BriaCell Therapeutics (BCT) has expanded its breast cancer platform technology into prostate, melanoma and lung cancers
- The new cell lines will be known as Bria-Pros for prostate cancer, Bria-Mel for melanoma and Bria-Lung for lung cancer
- The treatments focus on matching patients’ human leukocyte antigen molecules with the appropriate immunotherapy
- BriaCell is a biotechnology company focused on immuno-oncology developing targeted approaches for the management of cancer
- BriaCell Therapeutics (BCT) is up by 23.94 per cent and is currently trading at $9.06 per share
BriaCell Therapeutics (BCT) has expanded its breast cancer platform technology into prostate, melanoma and lung cancers.
The company’s immunotherapy treatment was most effective in breast cancer, specifically when the patients’ human leukocyte antigen molecules (HLA) matched with the targeted immunotherapy, allowing BriaCell to potentially identify patients likely to respond to the treatment.
BriaCell’s off-the-shelf personalized immunotherapies also make use of this HLA-matching technology. The new cell lines will be known as Bria-Pros for prostate cancer, Bria-Mel for melanoma and Bria-Lung for lung cancer.
The company expects clinical trials for its novel therapies to begin in 2022.
Bria-OTS for advanced breast cancer remains on track to commence patient dosing in 2021.
Dr. Bill Williams, BriaCell’s President and CEO, commented,
“We are thrilled about the prospects of our novel targeted off-the-shelf personalized immunotherapies for patients with advanced prostate cancer, melanoma and lung cancer. Working with our world-class scientists and collaborators, we look forward to bring these novel immunotherapies to patients in desperate need of new treatments.”
BriaCell is a biotechnology company focused on immuno-oncology developing targeted approaches for the management of cancer.
BriaCell Therapeutics (BCT) is up by 23.94 per cent and is currently trading at $9.06 per share as of 1:09 pm ET.
